Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

• ClinicalTrials.gov Identifier: NCT03064113
• Recruitment Status: Completed
• First Posted: February 24, 2017
• Results First Posted: November 14, 2019
• Last Update Posted: February 24, 2022
• Sponsor: Mylan Inc.
• Collaborator: Theravance Biopharma
• Information provided by (Responsible Party): Viatris Inc. ( Mylan Inc. )

Study Description

Brief Summary:

Thirty-two subjects diagnosed with COPD were enrolled, received each study treatment and completed the follow-up assessments. During each of the four study periods, subjects were admitted to the clinic on Day -1 and housed overnight until after the last spirometry measurement. Serial pulmonary function tests were performed and PK (pharmacokinetics) samples collected up to 25 hours. Subjects were discharged from the clinic on Day 2 after evaluations.

Condition or disease	Intervention/treatment	Phase
Chronic Obstructive Pulmonary Disease, COPD	Drug: Placebo; Drug: TD-4208 700 μg; Drug: TD-4208 350 μg; Drug: Ipratropium 500 μg	Phase 2

Detailed Description:

Subjects were assigned to one of the 4-treatment sequence groups presented in the table above according to a randomization schedule supplied by the Sponsor before study initiation. The randomization scheme did not include assignments for replacement subjects.

Subjects reported to their respective clinical research unit (CRU) on Admission/Day -1 for pre-randomization procedures and confirmation of eligibility (and continued eligibility for Periods 2 to 4). The unblinded pharmacist prepared and dispensed the nebulizers, according to the randomization schedule for each of the 4 periods. Dosing occurred in the morning, generally between 7 am and 9 am. For Periods 2 to 4, dosing occurred within ±30 minutes of the dosing time established in Period 1.

Study drug was administered in the respective CRU under the supervision of study personnel. Single doses of TD-4208, ipratropium bromide, and placebo were administered in the clinical research unit (CRU) under the supervision of study personnel. Care was taken to avoid eye contact with study drugs. Residual drug solution remaining in the nebulizer (ie, in mL) was measured and recorded.

The investigator or designee was responsible for maintaining accountability records for all study drug(s) in accordance with applicable government regulations and study procedures.

The accountability record included entries for receipt, distribution or dispensing, and destruction of the material(s). Unused and expired study drugs were to be disposed of in accordance with written instructions from the Sponsor.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 32 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease
• Study Start Date: May 2011
• Actual Primary Completion Date: October 2011
• Actual Study Completion Date: October 2011

Arms and Interventions

Arm	Intervention/treatment
Experimental: Sequence 1; Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg	Drug: Placebo; Drug: TD-4208 700 μg; Other Name: Revefenacin; Drug: TD-4208 350 μg; Other Name: Revefenacin; Drug: Ipratropium 500 μg
Experimental: Sequence 2; Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg	Drug: Placebo; Drug: TD-4208 700 μg; Other Name: Revefenacin; Drug: TD-4208 350 μg; Other Name: Revefenacin; Drug: Ipratropium 500 μg
Experimental: Sequence 3; Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg	Drug: Placebo; Drug: TD-4208 700 μg; Other Name: Revefenacin; Drug: TD-4208 350 μg; Other Name: Revefenacin; Drug: Ipratropium 500 μg
Experimental: Sequence 4; Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo	Drug: Placebo; Drug: TD-4208 700 μg; Other Name: Revefenacin; Drug: TD-4208 350 μg; Other Name: Revefenacin; Drug: Ipratropium 500 μg

Outcome Measures

Primary Outcome Measures :

1. Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline [ Time Frame: From predose to 25 hours postdose ]

Secondary Outcome Measures :

1. Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo [ Time Frame: 12 hr and 24 hr ]
2. Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo [ Time Frame: 12 hr and 24 hr ]
3. Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1 [ Time Frame: 12hr and 24hr ]
4. Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1 [ Time Frame: 12hr and 24hr ]
5. Forced Vital Capacity (FVC) [ Time Frame: From predose to 25 hours postdose ]
6. Area Under the Forced Vital Capacity (FVC) vs. Time Curve [ Time Frame: 0-24 hours ]

Eligibility Criteria

• Ages Eligible for Study: 40 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Diagnosis of moderate stable Chronic Obstructive Pulmonary.
• Disease with FEV1/FVC <0.7 at screening.
• Woman of non-childbearing potential.
• Female participants of childbearing potential must test negative for pregnancy and must be using a highly effective method of birth control during the study and for at least 1 month after completion of study dosing.
• Female participants must not be breastfeeding.
• Men must agree to use a highly effective method of birth control with partners of childbearing potential during the study and for 1 month after completion of study dosing.
• Current or past smoking history >10 pack-years.
• Must be capable of performing reproducible spirometry maneuvers.

Exclusion Criteria:

• History of significant respiratory disease other than COPD, and/ or requires daily long-term oxygen therapy.
• Exacerbation of COPD, lung infection within 6 weeks prior to study.
• Start of or change in dose of COPD treatment 4 weeks before study.
• Daily using of maintenance systemic/inhaled corticosteroids (>1000 microgram of fluticasone propionate equivalent or >5 mg prednisone).
• Use of bronchodilators or medication for the treatment of COPD, aspirin, anti-inflammatories for a specific time, prior to the first dose or is not willing to abstain from their use for the specified time periods prior to study dose administration.
• Symptomatic prostrate hypertrophy, bladder neck obstruction, active cancer, narrow angle glaucoma.
• Clinical significant hypersensitivity to medications.
• Participants have an uncontrolled hematologic, immunologic, renal, neurologic, hepatic, endocrine or other disease that may place participant at risk.
• Cerebrovascular, cardiovascular disease or abnormal ECG.
• History of drug or alcohol abuse.

Contacts and Locations

Locations

New Zealand

P3 Research

Wellington, New Zealand, 6021

Sponsors and Collaborators

Mylan Inc.

Theravance Biopharma

Investigators

• Study Director: Medical Monitor; Theravance Biopharma

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lo A, Borin MT, Bourdet DL. Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease. Clin Pharmacokinet. 2021 Mar;60(3):391-401. doi: 10.1007/s40262-020-00938-3.

• Responsible Party: Mylan Inc.
• ClinicalTrials.gov Identifier: NCT03064113
• Other Study ID Numbers: 0059; ACTRN12611000482965 ( Registry Identifier: ANZCTR ); U1111-1120-8290 ( Other Identifier: Universal Trial Number )
• First Posted: February 24, 2017
• Results First Posted: November 14, 2019
• Last Update Posted: February 24, 2022
• Last Verified: February 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Viatris Inc. ( Mylan Inc. ):

Chronic Obstructive Pulmonary Disease, COPD

Additional relevant MeSH terms:

Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Ipratropium; Bronchodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Asthmatic Agents; Respiratory System Agents; Cholinergic Antagonists; Cholinergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action